The crosstalk network of non-coding RNAs: Emerging opportunities for the clinical application of osteoporosis
Yan C., Wan Q., Fang Z., Sui C., Xiao X., Yang F.
Narrative Review, published in Noncoding RNA Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Noncoding RNA Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41503090
- PMCID
- PMC12771354
- DOI
- 10.1016/j.ncrna.2025.11.008
Abstract (original English)
Current methods for testing bone density lack the capability to detect patients with early bone loss, and existing osteoporosis therapies have limitations in their efficacy and safety. Therefore, the development of more precise and convenient diagnostic technologies and novel treatments is of paramount importance. Extracellular vesicle (EV)-mediated non-coding RNA (ncRNA) interaction networks enable both the detection of early bone loss and targeted therapy for enhanced treatment outcomes. In this review, we highlight the utility of EVs for carrying various ncRNAs (e.g., miRNAs, lncRNAs, and circRNAs) and thereby forming a complex regulatory network amongst bone-related cells such as osteoblasts and osteoclasts. The mechanisms through which EVs regulate bone cells and their potential for clinical translation are described in detail. Although the EV-mediated ncRNA network holds great promise for the precise diagnosis and targeted treatment of osteoporosis, rigorous large-scale studies are still required to address challenges related to its specificity and clinical application.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.